Palisade Asset Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Palisade Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9	Closed	-$182	–	628
2025 Q3	$182	Buy	+9	New	+$158	﹤0.01%	654

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Palisade Asset Management's TEVA Position: Q4 2025 in Review

Palisade Asset Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2025, closing a stake of 9 shares — an estimated $182 sold.

Palisade Asset Management first reported a position in TEVA in Q3 2025 and held it in 1 quarter. The position peaked at $182 in Q3 2025. 633 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

Palisade Asset Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2025 after selling out during the quarter.
Palisade Asset Management sold 9 Teva Pharmaceutical Industries Limited shares in Q4 2025, an estimated $182.
Palisade Asset Management first reported a position in Teva Pharmaceutical Industries Limited in Q3 2025 and held it in 1 quarter.
Palisade Asset Management's Teva Pharmaceutical Industries Limited position peaked at $182 in Q3 2025.
633 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2025.

Based on Palisade Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.